Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04629196 · ClinicalTrials.gov registry record · Phase 4
Induction Optimization With Stelara for Crohn's Disease
A Phase 4 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
NCT04629196 is a Phase 4 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 12 participants.
The verdict
NCT04629196, a Phase 4 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a 16-week randomized controlled trial comparing a second IV weight-based induction dose at week 8 to standard 90mg subcutaneous dose at week 8, with a primary endpoint of clinical remission at week 16.
Interventions
- DRUG Ustekinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-02-16 |
| Est. Completion | 2024-01-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04629196
The ClinicalTrials.gov registry entry for NCT04629196 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ustekinumab is the first listed.
NCT04629196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04629196 about?
NCT04629196 is a clinical study titled "Induction Optimization With Stelara for Crohn's Disease". This is a 16-week randomized controlled trial comparing a second IV weight-based induction dose at week 8 to standard 90mg subcutaneous dose at week 8, with a primary endpoint of clinical remission at week 16.
What is the current status of trial NCT04629196?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2022-02-16. Estimated completion is 2024-01-17.
What interventions are being tested in trial NCT04629196?
The interventions under investigation include: Ustekinumab (DRUG).
Who is sponsoring clinical trial NCT04629196?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.